1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
2. Hodi FS, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
3. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–26.
4. Margolin K, Wong SL, Penrod JR, et al. Effectiveness and safety of first-line ipilimumab (IPI) 3mg/kg therapy for advanced melanoma (AM): Evidence from a U.S. multisite retrospective chart review. Presented at: The European Cancer Congress. 2013; September 27–October 1; Amsterdam, The Netherlands (P488).
5. Patt D, Wong SL, Juday T, et al. Community-based, real-world, study of treatment-naïve advanced melanoma (AM) patients treated with 3mg/kg ipilimumab (IPI) in the United States. Presented at: The European Cancer Congress. 2013; September 27–October 1; Amsterdam, The Netherlands (P497).